Glecaprevir/pibrentasvir shows safety, efficacy in patients with HCV, renal disease

A recent study has shown that 102 out of 104 #HCV patients w/ advanced chronic kidney liver disease (98%) have achieved SVR12 (#hepatitis C is undetectable for twelve or more weeks after the end of treatment) with no virological failures. This is an indication that there is hope for patients with severe #HCV and liver disease.

Learn more here: bit.ly/2fyxLVE

oldestnewest